Condition: LGLL - Large Granular Lymphocytic Leukemia · Primary Cutaneous Gamma-Delta T-Cell Lymphoma · Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma · Sponsor: Dren Bio
This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
This description comes directly from the study's public registry record.
Dren Central Contact · 415-737-5277 · DR-01-ONC-001_inquiries@drenbio.com
Always discuss trial participation with your own doctor first.
| Dren Investigational Site | Birmingham, Alabama, United States | Recruiting |
| Dren Investigational Site | Duarte, California, United States | Recruiting |
| Dren Investigational Site | Irvine, California, United States | Recruiting |
| Dren Investigational Site | Redwood City, California, United States | Recruiting |
| Dren Investigational Site | New Haven, Connecticut, United States | Recruiting |
| Dren Investigational Site | Tampa, Florida, United States | Recruiting |
| Dren Investigational Site | Boston, Massachusetts, United States | Recruiting |
| Dren Investigational Site 1 | New York, New York, United States | Recruiting |
| Dren Investigational Site 2 | New York, New York, United States | Not Yet Recruiting |
| Dren Investigational Site | Columbus, Ohio, United States | Recruiting |
| Dren Investigational Site 2 | Pittsburgh, Pennsylvania, United States | Recruiting |
| Dren Investigational Site | Houston, Texas, United States | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05475925